The absorbed doses in the liver and adjacent viscera in Yttrium-90 radioembolization therapy for metastatic liver lesions are not well-documented. We sought for a clinically practical way to determine the dosimetry of this advent treatment. Six different female XCAT BMIs and seven different male XCAT BMIs were generated.
| INTRODUCTION
The treatment of inoperable liver metastases with microspheres and particles labeled with isotopes is a promising hope for a condition once was regarded untreatable. [1] [2] [3] [4] [5] The procedure is evolving and the radiations to lungs, preserved liver parenchyma, and the bone marrow in repeated treatments are the limiting concern. Patient's dosimetry is possible with simulation methods before the initiation of the treatment or can be calculated after the treatment for followup purposes. We previously used Monte Carlo code for certain conventional imaging and therapeutic agents including Technetium-99m, Iodine-131, and Samarium-153 in different phantoms 6, 7 and in patient. Recently 90 Y became available to us and labeling of the microspheres and clinical trials are under development. [8] [9] [10] There are different methods for internal dosimetry and imaging of the 90 Y. 11 In this study, we provide a radiation dose estimate to major target organs after treatment of liver metastases with the 90 Y Microspheres. The results are important for us before proceeding to the clinical use of the therapeutic agent. We define the procedure so that internal dosimetry become practical for the future uses. We employed GATE (GEANT4 Application to Tomographic Emission) 12 as a dedicated Mont Carlo code for nuclear medicine and XCAT 13 as an up-to-date hybrid phantom. Radiation Dose (MIRD) committee guideline. 16 To report the results in a more familiar way, the corresponding amount of equivalent dose (in mSv/s) were shown as well ( Fig. 1-4 ).
| MATERIAL AN D METHODS
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
| RESULTS
The successful uniform distribution of the tracer within the liver and the visual depiction of the deposited dose in the target organs are depicted in Fig. 5 . Also the radiation to the main target organs is presented in Table 1 in males and females. In all studied BMIs the radiation to the liver is remarkably higher than the lung and other target organs by the power of at least 100 ( | 177 absorbed doses in the liver are generally less than the target therapeutic dose for tumoricidal purposes of at least 80 Gy. 1 We put the therapeutic dose homogeneously within the liver, 18 but for the real practice one or more hepatic artery divisions could be catheterized 19 and hence the extent of the radiation would be probably higher.
1,2
Certain calculation methods are available to estimate the radiation to tumor and normal liver parenchyma. 20 With the same method using the patient's SPECT/CT data the exact radiation to the hepatic metastases could be calculated. Such data could be acquired by the injection of macroaggregated albumin tagged with Microspheres via the hepatic artery catheter. 21 There are methods for internal dosimetry based on MIRD formalism. In these methods, the activity deposition is concrete and less-flexible to match with the variations of the real activity in the patients. 18 For example to assess the lung shunt, the activity should be distributed uniformly in the lungs in these methods. Employing the simulation methods the real patient's SPECT/CT data could be used for this purpose. 22, 23 We also documented that although the dose to the bone marrow is generally low, the unwanted radiation into the bone marrow is unexpectedly high and about twice of others in thin patients with low BMIs; this would be the condition of many patients candidate In addition to the general radiation dependent side effects of 90 Y-microsphere including flu like syndrome and gastric ulceration, a more specific complication is radiation hepatitis. Post-treatment liver absorbed dose may assist the clinician to make sophisticated decisions including creation of portosystemic shunts when hepatic failure is encountered after radioembolization. The other concern is radiation lung fibrosis due to lung shunting of the tracer. The extent of the lung shunting should be ascertained with injection of 99m Tc-MAA. In this study the radiation to the lungs with no shunt was studied. The radiation to the kidney, lungs and bone marrow was presented as the sample critical organs but any organ of concern could be added into this list easily. We found that the radiation in the kidney and lugs are reasonably lower than the dose limitation of 15 to 30 Gy. 1 The absorbed dose in the bone marrow was negligible and below the threshold for even minor side effects (> 2 Gy). 24 There are few data available for comparison. The radiation to the tumor in real intra-arterial hepatic radioembolization was calculated to be about 76 Gy to the tumor by equation based calculation and 120-180 by MIRD approach which is comparable with the findings of the current study. 25, 26 The safe dose to non-tumoral liver parenchyma is considered less than 40 Gy. 22 The radiation to the kidneys and lungs secondary to treatment with 90 Y-Zevalin in patients with lymphoma unresponsive to chemotherapy are equal and much higher than the estimated dose in our study respectively. The distribution of the Zevalin and Intra-arterial hepatic radioembolization are different but the radiation dose to the lung and kidneys are comparably acceptable for the radioembolization. 27 The major shortcoming of the current study is the lack of simulation with real patient's data in different dose, metastasis location and employed spheres. 24 In fact the current data provoke us to precede the current simulation method in real clinical cases to consider enhancement of the future therapeutic administered doses.
| CONCLUSION
We provided the data of the radiation dose into the liver and certain critical organs after 90 Y-microsphere therapy. The dose to the liver with conventional administered dose of 3 GBq is lower than the therapeutic target and the unwanted radiation to the other viscera is very low. However, particular concern in the thin patients may be amended before 90 Y-microsphere therapy to avoid bone marrow suppression, escalation of the administered dose may be used safely.
The results should be confirmed in clinical setting.
